Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-09-22, Stock:LLY, The news for the past five days is as follows:
2020-09-15: NEWS1: Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know.NEWS2: Lilly's Olumiant Meets Primary Endpoint in Coronavirus Study.NEWS3: Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care.NEWS4: Steve Cohen Finally Buys the Mets. You Can Buy the Braves..NEWS5: US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack.
2020-09-16: NEWS1: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting.NEWS2: Eli Lilly Posts Positive Data On Covid-19 Treatment In Phase 2 Trials.NEWS3: Lilly's Coronavirus Antibody Treatment Found Effective, Safe In Mild-To-Moderate Patients.NEWS4: Eli Lilly Reports Success With COVID-19 Neutralizing Antibody Treatment.NEWS5: Lilly and Pfizer Are Testing Treatments for Hospitalized Covid Patients.NEWS6: Coronavirus update: Operation Warp Speed readies for vaccine as CDC tries to manage expectations.NEWS7: Dow Jones Rallies 200 Points Ahead Of Fed; Stocks Mixed As Nasdaq Falters.NEWS8: Eli Lilly Says Antibody Lowers Risk of Hospitalization for Mild COVID-19 Patients.NEWS9: Lilly Drug Gets Fast Track to Improve Heart Attack Outcome.NEWS10: Eli Lilly Says Covid-19 Treatment Reduces Hospitalizations.NEWS11: Shares of Lilly gain as it discloses promising interim findings for COVID-19 antibody treatment.NEWS12: Lilly says antibody reduces need for hospitalization for moderate COVID-19 patients.NEWS13: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting.NEWS14: The Argus Dividend Growth Portfolio.
2020-09-17: NEWS1: Eli Lilly, Amgen Teaming Up On Covid-19 Treatments.NEWS2: Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial.NEWS3: Race for a COVID-19 vaccine continues, here's what you need to know.NEWS4: Lilly's Coronavirus Antibody Shows Positive Effect in Phase II.NEWS5: Eli Lilly Reaches COVID-19 Antibody Therapy Manufacturing Deal With Amgen.NEWS6: Eli Lilly and Amgen to collaborate on COVID-19 antibody therapies.NEWS7: Lilly partners with Amgen for manufacturing potential COVID-19 drugs.NEWS8: Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies.NEWS9: 15 States With The Highest Diabetes Rates In U.S..
2020-09-18: NEWS1: Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments.NEWS2: Why Pfizer Is Seriously Mispriced.NEWS3: Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody.NEWS4: Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies.NEWS5: Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals.NEWS6: Coronavirus update: Global case tally tops 30 million, and controversial CDC testing guideline changes were reportedly not made by CDC scientists.NEWS7: A Look Into Eli Lilly's Debt.NEWS8: CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis.
2020-09-21: NEWS1: Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know.NEWS2: Pharma ETFs to Benefit from Lilly's Coronavirus Antibody Progress.NEWS3: Lilly's Olumiant Gets CHMP Nod for Eczema Label Expansion.NEWS4: Anticancer Drug Team-Ups Show Promise. 4 Stocks That Stand to Gain..NEWS5: Eli Lilly’s Verzenio Treatment Lowers Breast Cancer Recurrence By 25%.

Answer: Decrease